These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1186 related articles for article (PubMed ID: 26213211)

  • 21. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
    Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
    Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
    Chikhladze S; Lederer AK; Kousoulas L; Reinmuth M; Sick O; Fichtner-Feigl S; Wittel UA
    World J Surg Oncol; 2019 Nov; 17(1):185. PubMed ID: 31706323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades.
    Winter JM; Brennan MF; Tang LH; D'Angelica MI; Dematteo RP; Fong Y; Klimstra DS; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2012 Jan; 19(1):169-75. PubMed ID: 21761104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.
    Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R
    Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.
    Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG
    Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barriers to resection following neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma: A national and local perspective.
    Fromer MW; Mouw TJ; Scoggins CR; Egger ME; Philips P; McMasters KM; Martin RCG
    J Surg Oncol; 2024 Aug; 130(2):284-292. PubMed ID: 38828742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
    Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
    Tzeng CW; Fleming JB; Lee JE; Xiao L; Pisters PW; Vauthey JN; Abdalla EK; Wolff RA; Varadhachary GR; Fogelman DR; Crane CH; Balachandran A; Katz MH
    Ann Surg Oncol; 2012 Jun; 19(6):2045-53. PubMed ID: 22258816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
    Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
    Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
    Nakayama Y; Sugimoto M; Gotohda N; Konishi M; Takahashi S
    J Surg Res; 2018 Jan; 221():15-23. PubMed ID: 29229121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
    Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
    Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
    de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
    Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
    Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
    Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.